PAH News

October 17, 2019October 17, 2019

Adcirca-Opsumit Combo Beneficial as First-line Treatment for Newly Diagnosed PAH Patients, Trial Shows

News, PAH News

Treatment with Adcirca (tadalafil) plus Opsumit (macitentan) can provide functional benefits and lessen symptoms in newly diagnosed patients with pulmonary arterial hypertension (PAH), results from a clinical trial show. ... Read more

October 14, 2019October 14, 2019

Respira Reacquires Full Rights Over RT234 for As-Needed PAH Symptom Relief

News, PAH News

Respira Therapeutics has regained full worldwide research, development, and licensing rights over its inhaled medicine-device combination product, called RT234, for the treatment of pulmonary arterial hypertension (PAH). This follows ... Read more

October 7, 2019October 7, 2019

Positive Data Supports Advancing Rodatristat Ethyl to Phase 2 Trials in PAH Patients, Altavant Says

News, PAH News

Oral treatment with rodatristat ethyl is safe and well-tolerated, according to results from two completed Phase 1 clinical studies in healthy volunteers. These positive results support advancing the investigational ... Read more

October 3, 2019October 3, 2019

Blocking EYA3 Enzyme May Prevent Vascular Remodeling Seen in PAH, Study Suggests

News, PAH News, PH News

An enzyme involved in DNA damage processes, called EYA3, contributes to structural changes in lung blood vessels and to the progression of pulmonary hypertension (PH), according to a study ... Read more

September 30, 2019October 23, 2019

RNF213 Gene Variant a Risk Factor for Poor Outcomes, Treatment Resistance in PAH, Study Reports

News, PAH News

Patients with pulmonary arterial hypertension (PAH) who carry a specific mutation in the RNF213 gene have poor clinical outcomes and worse response to combination treatments, according to a study ... Read more

September 27, 2019September 27, 2019

PAH Incidence Rare in France But Carries High Economic Burden, Study Shows

News, PAH News

The incidence of pulmonary arterial hypertension (PAH) is rare in France, but it carries a high economic burden, a new study showed. The data were reported in “Hospital Burden ... Read more

September 25, 2019September 25, 2019

Translate Bio Focused on Developing New Candidates to Treat PAH, Other Pulmonary Diseases

News, PAH News

Translate Bio is focusing its efforts on the development of new therapies targeting pulmonary diseases, including pulmonary arterial hypertension and cystic fibrosis, among others. In light of this, the ... Read more

September 23, 2019September 25, 2019

Altavant Sciences Details Its ‘Patient-centric’ Approach to PAH Clinical Trials

News, PAH News

Altavant Sciences presented its patient-centered approach to drug development, which informed the design of an ongoing Phase 2 study, at the Pulmonary Hypertension Association’s recent Annual PH Professional Network ... Read more

September 13, 2019September 13, 2019

FDA Agrees to Review Trevyent, with PumpPatch System, as PAH Treatment

News, PAH News

The U.S. Food and Drug Administration (FDA) has agreed to review a request to approve Trevyent (treprostinil) as a treatment of pulmonary arterial hypertension (PAH), United Therapeutics announced in a press release. An ... Read more

September 9, 2019September 11, 2019

Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals

News, PAH News

Only two non-invasive diagnostic tests are required to best predict the risk of adverse events in people with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH), a new study ... Read more

Pin It on Pinterest